Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment

Shanghai Henlius Biotech said on 23 September 2026 that it has signed a global collaboration and licence agreement with US-based Amberstone Biosciences to develop conditionally activated T-cell engagers for solid tumours, using Amberstone’s T-MATE platform against up to 2 tumour antigens chosen by Henlius.
T-MATE builds a pH-sensitive switch into the molecule, so it stays inert at the neutral pH of normal tissue and activates in the acidic tumour microenvironment. Activation needs both target binding and acidic conditions, which is designed to cut off-tumour toxicity and widen the therapeutic window.
Amberstone will generate preclinical candidates, and Henlius will lead development, manufacturing and commercialisation. Amberstone receives an upfront payment, research fees, development, regulatory and sales milestones, and single-digit royalties. No amounts were disclosed.
Henlius, which has taken several monoclonal antibodies to approval, says it already runs T-cell, natural killer cell and myeloid cell engager platforms, plus its own selective activation platform designed to reduce the risk of cytokine release syndrome.

Deal read

Henlius bought a switch, not a molecule, and the deal discloses no dollar figure at all.

The only quantified term is a royalty ceiling. A single-digit royalty caps Amberstone’s share of any future product. It says nothing about what Henlius is paying now, and unlike the Orbis, BoomRay and Envisagenics deals this week there is not even a headline total.
The money flows the other way. A day after Novartis licensed a preclinical asset from Suzhou’s BoomRay, a Shanghai company is paying a US company for engineering. Henlius keeps its own targets and buys the activation technology, which positions it as a developer of first-in-class molecules rather than an out-licenser of them.
Henlius is backing the less-proven switch. The conditional T-cell engagers furthest into the clinic use protease-cleavable masks, including Janux’s TRACTr, Vir’s PRO-XTEN and CytomX’s Probody, and Bristol Myers Squibb partnered with Janux this year. pH-sensitive designs such as BioAtla’s EpCAM and CD3 bispecific have also entered trials, but the clinical responses cited in recent reviews come from protease-masked molecules.